What is NSIP ILD?
Nonspecific interstitial pneumonia (NSIP) is a distinct form of interstitial lung disease characterized by temporally uniform interstitial inflammation and/or fibrosis with preserved lung architecture, carrying a generally better prognosis than idiopathic pulmonary fibrosis but with variable clinical outcomes. 1
Key Diagnostic Features
Clinical Presentation
NSIP typically affects middle-aged patients (often women, frequently never-smokers) presenting with:
- Progressive dyspnea and cough
- Constitutional symptoms (fever, fatigue) in many cases
- Inspiratory rales on examination
- Mild hypoxemia
- Restrictive pattern on pulmonary function tests with reduced DLCO 2, 3
In your 80-year-old patient with recent ischemic heart disease and dyspnea, distinguishing NSIP from cardiac causes of dyspnea is critical—look specifically for bibasilar inspiratory crackles and restrictive physiology rather than signs of volume overload.
Radiologic Features (HRCT)
The most common HRCT findings include 1:
- Bilateral ground-glass opacities (most characteristic finding)
- Irregular reticular opacities with traction bronchiectasis/bronchiolectasis (~75% of cases)
- Subpleural sparing (helpful distinguishing feature from UIP)
- Lower lobe predominance
- Honeycombing is sparse or absent at presentation (key differentiator from IPF)
Histologic Features
Surgical lung biopsy shows 1:
- Varying amounts of interstitial inflammation and fibrosis with temporally uniform appearance (not patchy like UIP)
- Preserved alveolar architecture
- Most cases show predominantly fibrotic pattern; cellular NSIP is rare
- Organizing pneumonia and honeycomb fibrosis should be inconspicuous or absent
Critical Diagnostic Consideration
NSIP is NOT primarily an idiopathic disease—multidisciplinary discussion is essential to exclude secondary causes before diagnosing idiopathic NSIP. 1, 4, 3
The NSIP pattern occurs in multiple settings:
- Connective tissue diseases (most common secondary cause)
- Drug toxicity
- Hypersensitivity pneumonitis
- Environmental exposures
- Familial pulmonary fibrosis
- Autoimmune features (even without established CTD diagnosis)
For your elderly patient with cardiac disease, carefully evaluate medication history (amiodarone, methotrexate, chemotherapy agents) and assess for occult connective tissue disease with autoimmune serologies.
Prognosis and Natural History
The prognosis is variable but generally more favorable than IPF 1, 2:
- Some patients improve spontaneously or with treatment
- Others remain stable on therapy
- A subset progresses to end-stage fibrosis and death
- Honeycombing may develop during follow-up despite initial absence
In an 80-year-old with recent ischemic heart disease, the combination of cardiac comorbidity and potential for progressive fibrosis requires careful risk-benefit assessment of immunosuppressive therapy, as treatment carries significant risks in this population.
Distinguishing NSIP from UIP/IPF
Key differentiating features 1, 5:
NSIP:
- Subpleural sparing
- Minimal or absent honeycombing
- Temporally uniform histology
- Ground-glass predominance
- Better prognosis
UIP/IPF:
- Subpleural and basal predominance
- Honeycombing present
- Temporally heterogeneous (patchy fibrosis)
- Reticular pattern predominance
- Worse prognosis
Management Approach
Although not extensively evidence-based, treatment typically involves 4, 2, 3:
- Immunosuppression (corticosteroids ± immunosuppressive agents) for progressive or severe disease
- Close monitoring for disease progression
- Early clarification of treatment goals
- Consideration of antifibrotic therapies in progressive fibrotic cases (evolving evidence)
Common pitfall: Assuming all interstitial lung disease in elderly patients with cardiac disease is due to heart failure—NSIP requires active exclusion of secondary causes and multidisciplinary diagnosis involving pulmonology, radiology, and pathology expertise.